详情页 - 聚合机构库演示平台

当前位置：首页 > 详情页

HD-Idarubicin/Etoposide Intensified Conditioning Regimen Allo-HSCT for Adult ALL

124| 认领 | 链接全文 |

文献详情

编号/登记号：

注册时间：

研究开始时间：

研究结束时间：

项目类型：

本院角色：

多中心研究：

招募状态：

试验分期：

研究疾病/适应症：

研究类型：

研究参与人：

研究单位： [1]Nanfang Hospital of Southern Medical University [2]Department of Hematology,Tongji Hospital,Huazhong Science and Technology Wuhan,Hubei,China,430030 [3]Department of Hematology, Union Hospital, Huazhong Science and Technology Wuhan, Hubei, China, 430022 [4]Department of Hematology, 1st Affiliated Hospital of Guangxi Medical University Nanning, Guangxi, China, 530021 [5]Department of Hematology, Union Hospital of Fujian Medical University [6]Guangzhou General Hospital of Guangzhou Military Command Guangzhou, Guangdong, China, 510010 [7]Guangdong General Hospital Guangzhou, Guangdong, China, 510030 [8]Guangdong No.2 Provincial People's Hospital Guangzhou, Guangdong, China, 510317 [9]Department of Hematology, Nanfang Hospital, Southern Medical University [10]Third Affiliated Hospital, Sun Yat-Sen University Guangzhou, Guangdong, China, 510630 [11]Department of Hematology, 1st Guangzhou People Hospital Guangzhou, Guangdong, China [12]Oncology-Hematology Center, 1st Affiliated Hospital, Guangzhou Medical Collgege Guangzhou, Guangdong, China [13]Zhujiang Hospital of Southern Medical University Guangzhou, Guangdong, China [14]Zhongshan People Hospital,Guangdong Zhongshan, Guangdong, China, 528403

关键词： Idarubicin Etoposide HSCT Acute Lymphoblastic Leukemia

研究目的：

Intensified conditioning regimen allo-HSCT is based on a hypothesis of that intensifying condition with less-used drugs could overcome resistance,reduce tumor burden, and most importantly, spare enough time for slow-growing GVL effect following immune reconstitution to finally get rid of MRD and control the disease. Our previous trial of HDE-ALL-2011 (NCT01457040) have confirmed the role of intensified conditioning allo-HSCT in adult ALL, resulting in significantly improved OS and EFS in comparison with previous standard TBI/CY2 conditioning regimen(data not yet published). But at the same time, FA-TBI/CY2-VP16 conditioning regimen was associated with high transplantation-related mortality (TRM), which might be attributed to excessive suppression on both bone marrow and immune. TT-ALL-HIE-2013, substituting FA with idarubicin, is aimed at maintaining anti-tumor effect with less cross-resistance and immune suppression and reducing TRM.